Latest News and Press Releases

NeOnc (NASDAQ:NTHI) is developing therapies and delivery technologies targeting aggressive brain cancers and CNS-related conditions, and could be part of t

Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. $NTHI, $ORKA, $ABVX, $SYRE

Phase 2 and Phase 3 trials are reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders.

Biotechs continue attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy pla

Wall St analysts are rating NeOnc Technologies (NASDAQ:NTHI) a “Buy”, as institutional investors and company insiders are buying

Insider conviction, late-stage clinical wins, and platform technologies are converging to reshape biotech/pharma valuations and patient outcomes.

Insiders are buying shares of $NTHI, $RIVN, $SRAD, $NWBI, and $FGBI